Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DRD2 | P14416 | 1/20 | 0.53 |
| ▸ | CHRM4 | P08173 | 1/20 | 0.53 |
| ▸ | LMNA | P02545 | 2/20 | 0.52 |
| ▸ | UBE2M | P61081 | 6/20 | 0.52 |
| ▸ | DCUN1D1 | Q96GG9 | 6/20 | 0.52 |
| ▸ | SIGMAR1 | Q99720 | 2/20 | 0.49 |
| ▸ | FAAH | O00519 | 1/20 | 0.48 |
| ▸ | PKLR | P30613 | 1/20 | 0.47 |
| ▸ | CCR2 | P41597 | 1/20 | 0.47 |
| ▸ | NR3C1 | P04150 | 1/20 | 0.47 |
| ▸ | PGR | P06401 | 1/20 | 0.47 |
| ▸ | AR | P10275 | 1/20 | 0.47 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4193182 | 0.86 | DRD2 (0.51) | DRD2CHRM4PKLR | |
| SCHEMBL6351172 | 0.82 | CHRM4 (0.61) | DRD2CHRM4UBE2MDCUN1D1SIGMAR1 | |
| Hydrochloric Acid SCHEMBL4202752 | 0.82 | HSD17B2 (0.49) | DRD2LMNANR3C1PGRAR | |
| Hydrochloric Acid SCHEMBL4202759 | 0.82 | HSD17B2 (0.49) | DRD2LMNANR3C1PGRAR | |
| SCHEMBL9667283 | 0.79 | CHRM4 (0.69) | DRD2CHRM4UBE2MDCUN1D1SIGMAR1 | |
| SCHEMBL22608985 | 0.79 | DRD2 (0.57) | DRD2CHRM4ALDH1A1 | |
| SCHEMBL1546115 | 0.77 | DRD2 (0.55) | DRD2LMNAUBE2MDCUN1D1SIGMAR1 | |
| SCHEMBL1546113 | 0.77 | DRD2 (0.55) | DRD2LMNAUBE2MDCUN1D1SIGMAR1 | |
| SCHEMBL4204724 | 0.76 | TSHR (0.55) | LMNAPKLRNR3C1PGRAR | |
| SCHEMBL4193900 | 0.76 | NR3C1 (0.47) | LMNAPKLRNR3C1PGRAR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8642642-B2 | Heterocyclic arylsulphones suitable for treating disorders that respond to modulation of the serotonin 5HT6 receptor | ABBOTT LABORATORIES (US) | 2014-02-04 | — | — | US | disclosed |
| US-20090306175-A1 | HETEROCYCLIC ARYLSULPHONES SUITABLE FOR TREATING DISORDERS THAT RESPOND TO MODULATION OF THE SEROTONIN 5HT6 RECEPTOR | ABBOTT GMBH & CO. KG (DE) | 2009-12-10 | — | — | US | disclosed |
| EP-2029528-A1 | HETEROCYCLIC ARYLSULPHONES SUITABLE FOR TREATING DISORDERS THAT RESPOND TO MODULATION OF THE SEROTONIN 5HT6 RECEPTOR | Abbott GmbH & Co. KG (DE) | 2009-03-04 | — | — | EP | disclosed |
| WO-2007118899-A1 | HETEROCYCLIC ARYLSULPHONES SUITABLE FOR TREATING DISORDERS THAT RESPOND TO MODULATION OF THE SEROTONIN 5HT6 RECEPTOR | ABBOTT GMBH & CO. KG (DE) | 2007-10-25 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090306175-A1 | HETEROCYCLIC ARYLSULPHONES SUITABLE FOR TREATING DISORDERS THAT RESPOND TO MODULATION OF THE SEROTONIN 5HT6 RECEPTOR | HTR6, HTR1A, HTR5A | DRD2 116/4885CHRM4 309/4885LMNA 4039/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.